The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. These are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson and Schizophrenia.
With these new patents, Suven now has 17 granted patents from New Zealand, 16 from Singapore and 11 from South Korea. These granted patents are achieved through the company’s internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II, Suven said in a filing to the BSE.
Suven Life Sciences’ scrip is currently trading at Rs 44.95 on the BSE, up 2.98%, over the previous close of Rs 43.65.